Skip to content

Study · Animal study (in vivo) · mouse · 1991

7 results

Carrier-mediated transport of labeled oxytocin from brain to blood.

Durham DA, Banks WA, Kastin AJ

Neuroendocrinology1 May 1991Cited by 29 (Europe PMC)

PMID1678495 (opens in a new tab)DOI10.1159/000125756 (opens in a new tab)PepBankPUB-01678495
Publisher pagePubMedAsk about this study
Jump to 7 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Activity measurement

    In mice, unlabeled oxytocin inhibited labeled oxytocin transport, indicating a saturable transport component.

    In plain wordsIn mice, unlabeled oxytocin reduced transport of labeled oxytocin from brain to blood.

    Peptide
    Oxytocin
    Outcome
    DecreaseInhibition of labeled oxytocin transport
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 nmol/mouse · intraventricularAs given in this study (mouse).

    Source sentences

    Summary
    Inhibition by 10 nmol/mouse of oxytocin showed a saturable component to transport.
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.
  2. 02AnimalAnimal study (in vivo)Activity measurement

    In mice, MIF‑1 did not inhibit the transport system for labeled oxytocin.

    In plain wordsIn mice, MIF‑1 did not block labeled oxytocin transport from brain to blood.

    Peptide
    MIF-1 (Pro-Leu-Gly-NH2)
    Outcome
    No significant changeInhibition of labeled oxytocin transport
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    10 nmol · intraventricularAs given in this study (mouse).

    Source sentences

    Summary
    There was no inhibition of the system by a 10-nmol dose of tyrosine, iodotyrosine, MIF-1, or arginine vasopressin.
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.

Studies that did not test the peptide alone5

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 03AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Pharmacokinetics

    In mice, radiolabeled oxytocin had a central nervous system disappearance half-time of 19.1 min.

    In plain wordsIn mice, half of the labeled oxytocin disappeared from the central nervous system in 19.1 minutes.

    Peptide
    Oxytocin
    Outcome
    Not applicableCNS disappearance half-time
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology

    Measurements

    Disappearance half-time
    19.1 min
    central nervous system

    Source sentences

    Summary
    The half-time disappearance from the central nervous system of labeled oxytocin was 19.1 min.
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 04AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In mice, dual-tracer results were consistent with labeled oxytocin and Tyr-MIF-1 sharing peptide transport system-1.

    In plain wordsIn mice, tracer tests suggested that oxytocin and Tyr-MIF-1 used the same brain-to-blood transport system.

    Peptide
    Oxytocin
    Outcome
    Not applicableShared peptide transport system
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Studies performed with 125I-oxytocin injected simultaneously with 131I-Tyr-MIF-1 with or without unlabeled oxytocin or Tyr-MIF-1 were consistent with both peptides being transported by the previously described peptide transport system-1 (PTS-1).
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 05AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Activity measurement

    In mice, aluminum pretreatment inhibited transport of labeled oxytocin from brain to blood.

    In plain wordsIn mice, aluminum pretreatment reduced transport of labeled oxytocin from brain to blood.

    Peptide
    Oxytocin
    Outcome
    DecreaseTransport after aluminum pretreatment
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Pretreatment with aluminum (100 mg/kg of elemental aluminum given 60-90 min before intraventricular injection), previously shown to inhibit PTS-1 and some other transport systems, inhibited the transport of labeled oxytocin.
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  4. 06AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Other

    In mice, blood radioactivity after brain injection of labeled oxytocin coeluted with the labeled oxytocin standard.

    In plain wordsIn mice, blood tracer tests matched the labeled oxytocin standard after brain injection.

    Peptide
    Oxytocin
    Outcome
    Not applicableBlood tracer chromatographic identity
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    Radioactivity collected from the blood after intraventricular injection of 125I-oxytocin eluted on HPLC at the same position as the labeled oxytocin standard and differently from tyrosine, Tyr-MIF-1, MIF-1 and tocinamide.
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  5. 07AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Activity measurement

    In mice, Tyr-MIF-1 and pressinamide significantly inhibited transport of labeled oxytocin.

    In plain wordsIn mice, Tyr-MIF-1 and pressinamide reduced transport of labeled oxytocin.

    Peptide
    Oxytocin
    Outcome
    DecreaseTransport inhibition by Tyr-MIF-1 and pressinamide
    Study

    mousen: not reported in source

    Brain-to-blood peptide transport
    Outcome group
    Pharmacokinetics · Pharmacology

    Source sentences

    Summary
    A 10-nmol dose of tyrosine-melanocyte-stimulating hormone release inhibiting factor (Tyr-MIF-1) and pressinamide also significantly inhibited transport of labeled oxytocin (p less than 0.05).
    1 context sentence
    Summary · context
    The transport of 125I-oxytocin from brain to blood was investigated in mice after intraventricular injection of radioactively labeled oxytocin with or without unlabeled candidate inhibitors.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 2

    21 Oct 2026, 18:59 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 02:51 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.